Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Neeb

Showing results (1-10 of 69) with videos related to

Pageof 7
Sort By:
Current Pain and Headache Reports|April 7, 2018
CGRP Monoclonal Antibodies for the Preventative Treatment of MigraineHeike Israel, Lars Neeb, Uwe Reuter
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|May 1, 2010
5-HT(1F) Receptor agonists: a new treatment option for migraine attacks?Lars Neeb, Jannis Meents, Uwe Reuter
Therapeutic Advances in Neurological Disorders|January 14, 2015
The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraineUwe Reuter, Heike Israel, Lars Neeb
MMW Fortschritte Der Medizin|June 24, 2019
[Migraine - therapy in transition]Katharina Kamm, Andreas Straube, Lars Neeb
Expert Opinion on Biological Therapy|September 26, 2019
Monoclonal antibodies for the prevention of migraineBianca Raffaelli, Lars Neeb, Uwe Reuter
MMW Fortschritte Der Medizin|July 18, 2019
Katharina Kamm, Andreas Straube, Lars Neeb
Trends in Molecular Medicine|March 30, 2010
TRPV1 in migraine pathophysiologyJannis E Meents, Lars Neeb, Uwe Reuter
Expert Review of Neurotherapeutics|January 8, 2019
Erenumab for episodic migraine prophylaxisLucas Hendrik Overeem, Lars Neeb, Uwe Reuter
Expert Opinion on Pharmacotherapy|July 28, 2017
The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraineBianca Raffaelli, Heike Israel, Lars Neeb, et al.
Deutsche Medizinische Wochenschrift (1946)|March 23, 2017
[Pathophysiology of Headaches]Charly Gaul, Karl Meßlinger, Dagny Holle-Lee, et al.
Pageof 7

Showing results (1-10 of 69) with videos related to

Sort By:
Pageof 7
Current Pain and Headache Reports|April 7, 2018
CGRP Monoclonal Antibodies for the Preventative Treatment of MigraineHeike Israel, Lars Neeb, Uwe Reuter
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|May 1, 2010
5-HT(1F) Receptor agonists: a new treatment option for migraine attacks?Lars Neeb, Jannis Meents, Uwe Reuter
Therapeutic Advances in Neurological Disorders|January 14, 2015
The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraineUwe Reuter, Heike Israel, Lars Neeb
MMW Fortschritte Der Medizin|June 24, 2019
[Migraine - therapy in transition]Katharina Kamm, Andreas Straube, Lars Neeb
Expert Opinion on Biological Therapy|September 26, 2019
Monoclonal antibodies for the prevention of migraineBianca Raffaelli, Lars Neeb, Uwe Reuter
MMW Fortschritte Der Medizin|July 18, 2019
Katharina Kamm, Andreas Straube, Lars Neeb
Trends in Molecular Medicine|March 30, 2010
TRPV1 in migraine pathophysiologyJannis E Meents, Lars Neeb, Uwe Reuter
Expert Review of Neurotherapeutics|January 8, 2019
Erenumab for episodic migraine prophylaxisLucas Hendrik Overeem, Lars Neeb, Uwe Reuter
Expert Opinion on Pharmacotherapy|July 28, 2017
The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraineBianca Raffaelli, Heike Israel, Lars Neeb, et al.
Deutsche Medizinische Wochenschrift (1946)|March 23, 2017
[Pathophysiology of Headaches]Charly Gaul, Karl Meßlinger, Dagny Holle-Lee, et al.
Pageof 7